Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
ZTS
BUYZoetis Inc. · Healthcare · United States · $31.9B · Avg Vol: $525M/d
COMPANY DESCRIPTION
Zoetis Inc. is the world's largest animal health company, dedicated to discovering, developing, and manufacturing a comprehensive portfolio of medicines, vaccines, and diagnostic products for livestock and companion animals. The company benefits from its unparalleled scale, extensive R&D, and deep relationships with veterinary professionals and farmers globally, establishing a strong leadership position in a growing market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.1B | 8.5B | 9.3B | 9.5B | 5.4% | 9.5B | 9.8B | 10.2B | 3.6% |
| EPS | 4.51 | 5.08 | 5.47 | 6.03 | 10.2% | 6.10 | 6.46 | 6.96 | 7.4% |
| Shares | 463.8M | 458.4M | 448.5M | 424.9M | -8.4% | 419.2M | — | — | — |
| Debt | 8.1B | 6.8B | 6.7B | 9.2B | 4.5% | 9.3B | — | — | — |
| Equity | 4.4B | 5.0B | 4.8B | 3.3B | -8.9% | — | — | — | — |
| Op CF | 1.9B | 2.4B | 3.0B | 2.9B | 14.9% | 2.8B | — | — | — |
| Inv CF | -883.0M | -777.0M | -315.0M | -748.0M | — | — | — | — | — |
| Fin CF | -904.0M | -3.1B | -2.7B | -1.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZTS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZTS | Zoetis Inc.(you) | $31.9B | 71 | BUY |
| UTHR | United Therapeutics Corporation | $23.0B | 88 | STRONG BUY |
| ELAN | Elanco Animal Health Incorporated | $12.3B | 64 | HOLD |
| VTRS | Viatris Inc. | $19.0B | 88 | STRONG BUY |
| NBIX | Neurocrine Biosciences, Inc. | $16.9B | 93 | STRONG BUY |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.5B | 88 | STRONG BUY |
| LQDA | Liquidia Corporation | $7.0B | 48 | HOLD |
| LNTH | Lantheus Holdings, Inc. | $7.1B | 94 | STRONG BUY |
| INDV | Indivior Pharmaceuticals, Inc. | $4.9B | 90 | STRONG BUY |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.7B | 62 | HOLD |
Peer medians: ROE -22.1% · P/E 27.4x · Gross margin 48.7%